Similar diagnostic utility has been reported for CDH1 in breast cancer (Xie et al., 2022; Huang, Ding & Yang, 2015; Corso et al., 2024) and CDH2 in gastric cancer (Zhao et al., 2021; Zhang et al., 2024), supporting their potential as universal biomarkers across cancers. This evidence concerns the gene CDH2 and gastric cancer.